RMTI (Rockwell Medical) ROCE %: -11.13% (As of Mar. 2026)

What is Rockwell Medical ROCE %?

Rockwell Medical RMTI +0.75% 32 ROCE % is -11.13% as of Mar. 2026. GuruFocus rates RMTI with a GF Score™ of 32/100 and a GF Value™ of $0.87 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rockwell Medical's annualized ROCE % for the quarter that ended in Mar. 2026 was -11.13%.

Rockwell Medical (NAS:RMTI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rockwell Medical ROCE % Related Terms

Rockwell Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical ROCE % Chart

Rockwell Medical Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-65.50

-59.21

-19.04

1.92

-9.04

Rockwell Medical Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-11.27	-11.52	-13.11	-2.25	-11.13

32GF Score

Rockwell Medical Inc RMTI

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Rockwell Medical ROCE % Calculation

Rockwell Medical's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-4.19	/	( ( (59.208 - 14.091)	+	(57.145 - 9.58) )	/ 2 )
	=	-4.19	/	( (45.117	+	47.565)	/ 2 )
	=	-4.19	/	46.341
	=	-9.04 %

Rockwell Medical's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-5.292	/	( ( (57.145 - 9.58)	+	(57.423 - 9.868) )	/ 2 )
	=	-5.292	/	( ( 47.565	+	47.555 )	/ 2 )
	=	-5.292	/	47.56
	=	-11.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -11.13% mean?

Rockwell Medical (RMTI) has a ROCE % of -11.13% as of Mar. 2026.

Is Rockwell Medical's ROCE % too high?

Rockwell Medical's current ROCE % is -11.13%. Overall, Rockwell Medical has a GF Score™ of 32/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Rockwell Medical's ROCE % compare to MRMD and CPHI?

Rockwell Medical's ROCE % of -11.13% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current ROCE % is -11.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Rockwell Medical stock overvalued right now?

Based on GuruFocus' analysis, Rockwell Medical (RMTI) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.87, compared to a current price of $0.68 — trading 21.3% below its estimated fair value. The current ROCE % is -11.13%. Rockwell Medical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Rockwell Medical (RMTI), the current ROCE % is -11.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (RMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued. The current stock price of $0.68 is trading 21.3% below its estimated GF Value™ of $0.87. GuruFocus considers Rockwell Medical to be Modestly Undervalued.

Key valuation signals for RMTI:

ROCE %: -11.13%
GF Value™: $0.87 vs. price of $0.68 (21.3% below fair value)
GF Score™: 32/100 with 3 warning signs

No single metric tells the full story. See the RMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rockwell Medical Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies MRMD CPHI HYEX AYTU TXMD KAYS BTAI APUS ZYBT IXHL XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges RWMA:Germany

Address 30142 South Wixom Road, Wixom, MI, USA, 48393

Website https://www.rockwellmed.com

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.

32GF Score

Get the complete analysis for RMTI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68

Price

$0.87

GF Value

View RMTI Analysis

See ROCE % data for all stocks →